Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism

NCT ID: NCT02675530

Last Updated: 2016-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-12-31
• Study Completion Date: 2011-12-31

Brief Summary

This study investigates the common features of electrophysiological measures in schizophrenia and effects of NMDA antagonist ketamine in healthy volunteers.

Conditions

Schizophrenia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: NONE

Study Groups

healthy control

Healthy controls will receive electrophysiological assessments before and after NMDA antagonist administration.

Group Type: EXPERIMENTAL

ketamine

Intervention Type: DRUG

For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.

No drug administration for patients with schizophrenia

Interventions

ketamine

For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.

No drug administration for patients with schizophrenia

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female

2. 21-45 years old

3. Deemed healthy by the Structured Clinical Interview for DSM-NP (SCID-NP) and collateral information. Subjects will need to provide the name of a person, preferably a family member, whom the research team can contact to corroborate information.

1. Male or female

2. 21-45 years old

3. No past or present Axis I diagnosis, as determined by the SCID-NP

1. Male or female

2. 21-45 years old

3. Diagnosed with DSM-IV schizophrenia based on a SCID-IP interview for patients.

4. Stable dose of antipsychotic medications for at least 2 weeks prior to beginning study participation.

5. Score either in the 1-3 (high functioning) range or in the 5-7 (low functioning) range of the Global Functioning Scale from the MSIF based on a screening interview.

Exclusion Criteria

1. Lifetime diagnosis of DSM-IV substance dependence (except caffeine and nicotine).

2. Substance abuse, as per clinical judgment, in the past 1 year.

3. Current or past DSM-IV Axis-I diagnosis.

4. A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic or neurological. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up.

5. A hearing deficit greater than 30 dB in both ears detected using a Welch-Allyn audioscope (500, 1000, 2000 and 4000 Hz threshold will be evaluated) at screening.

6. Major current or recent (<6 weeks) stressors.

7. History of counseling, except if counseling was for a life circumstance disorder (e.g., bereavement, divorce) or in the opinion of the investigator, is not clinically significant.

8. Lifetime history of treatment with any psychotropic medications for > 1 month duration suggestive of psychiatric illness.

9. Current or past Axis I diagnosis of schizophrenia or bipolar disorder in first-degree relatives.

10. Any medication that could interfere with either the safety of the study and/or the outcome measures.

11. Use of any illicit substances in the 4 weeks prior to beginning study participation.

12. Any history indicating learning disability, mental retardation, or attention deficit disorder.

13. History of head injury with loss of consciousness greater than fifteen minutes.

14. Any other condition or medication, which in the opinion of the investigator would preclude participation in the study.

15. Non-English speaking.

16. Known sensitivity to ketamine.

Subjects for the Schizophrenia experiment:

1. Lifetime diagnosis of DSM-IV substance dependence (except caffeine and nicotine).

2. Substance abuse, as per clinical judgment, in the past 1 year

3. A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic or neurological.

4. A hearing deficit greater than 30dB in both ears detected using a Welch-Allyn audioscope (500, 1000, 2000 and 4000 Hz threshold will be evaluated) at screening.

5. Axis I diagnosis of schizophrenia or bipolar disorder in first-degree relatives.

6. History of head injury with loss of consciousness greater than fifteen minutes

7. Any other condition or medication, which in the opinion of the investigator would preclude participation in the study.

8. Non-English speaking.

1. Lifetime diagnosis of DSM-IV substance dependence (except caffeine and nicotine).

2. Substance abuse, as per clinical judgment, in the past 1 year

3. A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic or neurological.

4. A hearing deficit greater than 30dB in both ears detected using a Welch-Allyn audioscope (500, 1000, 2000 and 4000 Hz threshold will be evaluated) at screening.

5. History of head injury with loss of consciousness greater than fifteen minutes.

6. Any other condition or medication, which in the opinion of the investigator would preclude participation in the study.

7. Non-English speaking.

-

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

Yale University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Handan Gunduz-Bruce, M.D.

Role: PRINCIPAL_INVESTIGATOR

Yale Medical School

Locations

VHA CT

West Haven, Connecticut, United States

Countries

United States

Other Identifiers

0612002073

Identifier Type: -

Identifier Source: org_study_id